Develop Health vs SamaCare
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Develop Health | SamaCare | |
|---|---|---|
| Pricing model | Free to providers (funded by payers/pharma) · pharma-funded, free for prescribers | Free to providers (funded by payers/pharma) · Pharma funds premium services and data |
| Speed to go live | API integration into existing EHR workflow | Web portal, no IT project required |
| Automation model | Autonomous agents · automated benefit checks and PA submission | Software platform · Unified PA portal, AI touchless tier |
| Built for | Small practices, Mid-size groups, Enterprise systems | Small practices, Mid-size groups |
| Security posture | HIPAA | SOC 2 Type I, HIPAA |
| Company maturity | 4 yrs (est. 2022) | 8 yrs (est. 2018) |
| Financial backing | $17.6M · Series A | $33M+ · Series B |
| Named customers | 4 named | None public |
| Published results | No public numbers | No public numbers |
| Documented integrations | 2 listed | 4 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick Develop Health if medication prior auths bottleneck your prescribers and you want end-to-end PA automation at no cost to the practice.
- Pick SamaCare if you are a specialty practice buried in medical-benefit prior auths and want one free web portal replacing faxes and payer portals today.
Develop Health
AI benefit verification and prior auth for prescriptions
- Founded
- 2022
- HQ
- Menlo Park, CA
- Stage
- Series A
- Raised
- $17.6M
What it does
- Real-time benefit verification with plan-specific cost and coverage
- Predicts coverage and PA requirements at point of prescription
- Generates and submits prescription prior authorization packages
- Drafts appeals and manages denials automatically
- Returns structured coverage data into the prescriber's EHR
Where it's strong
- Purpose-built for prescription drug access (benefit checks plus medication PA), a narrower and deeper wedge than general prior auth vendors.
- Named traction with high-volume telehealth prescribers like Ro and LifeMD, where GLP-1 coverage friction makes the ROI easy to measure.
- Founders came from Canvas Medical and Rupa Health, so the product is built around real prescriber workflow integration rather than a standalone portal.
What buyers should weigh
- Total funding of $17.6 million and a 2022 founding date make this an early-stage vendor bet; assess team depth and support model before committing core volume.
- Public proof points are concentrated in telehealth and virtual care companies, so traditional health systems and pharmacies will find fewer reference customers.
- Scope is medications only; if you also need procedure, imaging, or DME prior auth, you will still need another vendor.
Named customers
Ro · LifeMD · Calibrate · Sunrise
Integrations
SamaCare
Prior authorization platform for buy-and-bill specialty drugs
- Founded
- 2018
- HQ
- San Francisco, CA
- Stage
- Series B
- Raised
- $33M+
What it does
- One portal for all medical benefit PA submissions
- AI-assisted form completion and payer requirements
- Status tracking, renewals, and expiration alerts
- Benefit verification and enrollment workflows
- Approval analytics across a 20K-provider network
Where it's strong
- Purpose-built for buy-and-bill drugs, a workflow retail-focused PA tools handle poorly.
- Free for practices because pharma funds it, which removes the budget fight.
- Network data from roughly 20,000 providers improves payer form accuracy and approval odds.
What buyers should weigh
- The pharma-funded model means manufacturers see aggregate data; understand the data terms before signing.
- Scope is medication PA for specialty drugs, not procedures, imaging, or surgical auths.
- Smaller company (Series B) than incumbent networks, so vendor risk is higher than with McKesson or Optum.
Integrations
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.